NASDAQ:OMER

Omeros Stock News

Healthcare > Biotechnology

Buy OMER

*Your capital is at risk

$10.16

-0.1000 (-0.97%)

At Close: Jun 03, 2026

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

08:57pm, Monday, 31'st Mar 2025

Omeros Corporation (NASDAQ:OMER ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Jennifer Williams - Investor and Media relations, Cook Williams Communications, Inc. G

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

04:02pm, Monday, 31'st Mar 2025

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024, whi

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

07:39am, Friday, 28'th Mar 2025

Omeros Corporation OMER will release its fourth-quarter financial results after the closing bell on Monday, March 31.

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

09:15am, Wednesday, 26'th Mar 2025

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024, on Monday, March 31, 20

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

09:15am, Friday, 21'st Mar 2025

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company's Phase 3 program evaluating zaltenibart in pa

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

04:44pm, Monday, 24'th Feb 2025

Omeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical an

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

09:10am, Thursday, 20'th Feb 2025

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros' first-in-class monoclonal

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

09:00am, Friday, 14'th Feb 2025

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings – the Transp

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

09:00am, Monday, 10'th Feb 2025

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of t

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

12:28pm, Thursday, 19'th Dec 2024

On Thursday, Omeros Corporation OMER announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab.

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

09:15am, Thursday, 19'th Dec 2024

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Om

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by